Sector News

Could a restructuring help protect AbbVie when revenue troubles hit?

April 15, 2015
Life sciences
It’s no secret that AbbVie’s sales are in for a shock once generic competition starts eating away at behemoth Humira. But worry not, investors: The company will be able to shield its EPS from the hit when the time comes, one analyst believes.
 
According to ISI Evercore’s Mark Schoenebaum, the Illinois pharma “has the ability to protect EPS to a far larger ability than the Street currently understands,” he wrote in a Tuesday note to investors.
 
Does that mean another Big Pharma slim-down is imminent? Not necessarily, Schoenebaum said. “I am NOT making the call that the company should (or would) immediately restructure,” he wrote. But he does hope AbbVie “will acknowledge that it, in theory, has such cost flexibility should the revenue situation underperform their expectations over the next decade.”
 
If AbbVie did decide to shed some pieces, it would hardly be alone in its thinking. More than a few of its Big Pharma peers–including Pfizer, Novartis and Merck–have recently hived off non-core assets to focus on what they do well and boost financial performance. AbbVie itself is the product of a divestment: One-time parent Abbott Labs spun the drugmaker off in early 2013.
 
Lately, though, AbbVie has been all about bulking up to ease the revenue blow when it comes. After nixing last year’s Shire tie-up on tax reasons, it recently agreed to fork over $21 billion to gain access to Pharmacyclics’ Imbruvica, a drug it said would bring it $7 billion in peak sales.
 
Still, though, $11 billion seller Humira–which brings in the vast majority of AbbVie’s top-line haul–will leave big shoes to fill. The med already has biosimilar competition in India, and with its U.S. patent protection set to expire in 2016, some industry-watchers think its business could start suffering sooner rather than later.
 
“At year 3, biosimilars will achieve 36% U.S. market share in Humira patients and 25% in established Humira patients,” Citi’s Andrew Baum wrote in February, predicting Humira revenues would decline from a peak $16 billion in 2017 to just $6 billion in 2022.
 
By Carly Helfand
 

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach